New Journey(002219)2025-04-28 17:55Financial Performance - The company's revenue for Q1 2025 was ¥796,152,158.94, representing a decrease of 16.49% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥25,651,871.15, down 9.35% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.0076, reflecting an 8.43% decrease from the previous year[5]. - Total operating revenue decreased to ¥796,152,158.94 from ¥953,406,293.16, representing a decline of approximately 16.5% year-over-year[18]. - Net profit for the period was ¥24,568,864.12, down from ¥30,278,299.46, reflecting a decrease of approximately 18.5% year-over-year[19]. - The net profit attributable to the parent company was ¥25,651,871.15, compared to ¥28,298,589.87, a decline of about 9.2% year-over-year[19]. Cash Flow - The net cash flow from operating activities was negative at -¥37,994,893.16, a decline of 295.69% compared to the previous year[5]. - The net cash flow from operating activities was -37,994,893.16, compared to 19,415,797.80 in the previous period, indicating a decline in operational cash generation[21]. - Total cash inflow from financing activities was 905,404,638.47, up from 525,764,043.63, reflecting increased borrowing and investment receipts[22]. - The net cash flow from financing activities was 265,867,299.41, a significant improvement from -28,626,219.91 in the previous period, indicating better financing conditions[22]. - The net cash flow from investing activities was -281,232,018.53, compared to -85,999,556.27 previously, showing a significant increase in cash outflows for investments[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,697,480,188.77, an increase of 0.30% from the end of the previous year[5]. - The company's total assets amount to approximately 6.70 billion RMB, with a slight decrease from 6.68 billion RMB at the beginning of the period[15]. - Total liabilities amounted to ¥4,625,175,397.49, slightly down from ¥4,636,462,586.44, a decrease of approximately 0.2%[17]. - Total equity increased to ¥2,072,304,791.28 from ¥2,040,729,633.97, reflecting an increase of about 1.5%[17]. Research and Development - The company's R&D expenses increased by 30.52% to ¥4,398,653.82 due to higher external R&D spending[9]. - Research and development expenses rose to ¥4,398,653.82 from ¥3,370,011.31, an increase of approximately 30.4% year-over-year[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 66,333[12]. - The largest shareholder, Beijing New Mileage Health Industry Group Co., Ltd., holds 24.38% of shares, totaling 825,927,323 shares[12]. - The top ten shareholders include various investment funds and individuals, with significant holdings and some shares under pledge or freeze[12][13]. Operational Metrics - Cash received from sales of goods and services was ¥716,100,676.97, down from ¥890,867,731.57, indicating a decrease of about 19.6% year-over-year[20]. - Cash outflows for operating activities totaled 767,237,059.59, compared to 887,874,207.46 in the previous period, showing a reduction in operational expenses[21]. - Cash inflow from other operating activities was 13,141,489.46, compared to 16,422,273.69 previously, indicating a decline in miscellaneous operational cash receipts[21]. - The company reported a credit impairment loss of ¥4,123,361.88, compared to a loss of ¥9,800,623.67 in the previous period, indicating an improvement in credit quality[18].